apo.com Group grows faster than the market – revenue increases to EUR 342 million in 2024
- Revenue increase of 17% to EUR 342 million outperforms market growth
- Investments in digitization, automation and pharmaceutical personnel enable rapid scaling of e-prescription business
- Marketing campaigns increase awareness of apodiscounter.de, apo.com and e-prescriptions
Leipzig, 20.02.2025 – In 2024, the apo.com Group increased its revenue by 17% to €342 million. The group thus outperformed the market growth of 11%*, which is strongly influenced by the market leader and the apo.com Group itself. This makes the apo.com Group one of the fastest growing online pharmacy groups in the German market.
Our revenue growth proves that we have set the right course to benefit from e-prescriptions. In 2025, we are focusing on further expanding our business areas based on e-prescriptions and strengthening our position as the third-largest online pharmacy group in the German market.
Dr. Oliver Scheel, CEO at apo.com Group
Growth through digitalization and e-prescriptions
In 2024, the apo.com Group has invested heavily in digital infrastructure to efficiently scale its e-prescription business. The introduction of CardLink technology enables customers to redeem e-prescriptions directly via their health cards in the new native apps from apo.com and apodiscounter.de. Since the launch at the end of October 2024, the e-prescription business has seen a revenue growth of over 50%, which has accelerated to over 70% since January 2025. This momentum confirms the great potential of e-prescriptions for the apo.com Group.
The group expects to see further acceleration in the growth of the e-prescription business over the course of the year, with significant revenue increases resulting from the increasing acceptance of e-prescriptions. The German prescription drug market has a volume of over €65 billion. apo.com Group believes it is very well positioned to capture a disproportionately large share of the rapidly growing e-prescription market.
Investments in logistics automation and pharmaceutical personnel
To take the e-prescription business to the next level, the apo.com Group is also investing in efficient logistics and highly qualified pharmaceutical specialists. The group’s modern logistics center in Duiven (Netherlands) sets new standards in the field of automation. This enables the efficient processing of increasing numbers of e-prescription orders and improves the cost structure. In addition, the apo.com Group has expanded its pharmaceutical team by 50% and is investing in an efficient process chain for prescription processing. With a combination of AI-supported logistics processes and pharmaceutical expertise, the apo.com Group is ideally positioned to scale its e-prescription business in 2025 and ensure the highest security standards in the supply of medication.
Marketing campaigns: 20 years of apodiscounter.de and the new e-prescription
One outstanding event in 2024 was the 20th anniversary of apodiscounter.de – the oldest and best-known brand among the nine online pharmacies of the apo.com Group. For two decades, apodiscounter.de has established itself as a leading discounter brand with high customer loyalty and remains a central growth driver of the group. Since November 2024, two 360-degree marketing campaigns have also been strengthening awareness of digital e-prescription redemption among the main brands apodiscounter.de and apo.com.
Outlook for 2025: consolidate market position, improve supply of medicines
For 2025, the apo.com Group has set itself the goal of strengthening its market position as the third-largest online pharmacy group in Germany and improving the supply of medicines. The digital offering is an indispensable component, especially for people with chronic illnesses and in rural areas.
We are convinced that 2025 will be the year in which e-prescriptions become an increasingly important part of people’s everyday lives. With digital solutions, our highly automated logistics and qualified personnel, we will continue to shape digital healthcare.
Dr. Oliver Scheel, CEO at apo.com Group
*Source: DatamedIQ